The Top 5 Biosimilar Articles for the Week of May 26

Number 5: Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective vascular endothelial growth factor inhibition.

Number 4: Eculizumab biosimilars could provide European patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome better access to care for a better price, similar to successes seen in other biosimilar markets, according to a review.

Number 3: Dose escalations were more frequent with ustekinumab in patients with psoriasis compared with adalimumab and etanercept, highlighting varied outcomes for dose optimization in psoriasis management.

Number 2: Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.

Number 1: Sarfaraz K. Niazi, PhD, asserts that India's recently revised 2025 biosimilar guidelines represent a significant and rational step towards global regulatory alignment by deemphasizing animal and human efficacy testing in favor of scientifically robust, risk-based, and ethically sound frameworks.

To read all of these articles and more, visit centerforbiosimilars.com.